Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2024

This “Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Relapsed or Refractory Myelodysplastic Syndrome Understanding

Relapsed or Refractory Myelodysplastic Syndrome: Overview

Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML).Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3. The goals of therapy for patients with MDS are to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both quality and quantity of life. Some patients may have no symptoms of disease. MDS may be detected before symptoms appear, as a result of laboratory tests that were part of a routine medical examination. Treatment for myelodysplastic syndromes includes supportive care, drug therapy, and stem cell transplantation.

Relapsed or Refractory Myelodysplastic Syndrome- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape is provided which includes the disease overview and Relapsed or Refractory Myelodysplastic Syndrome treatment guidelines. The assessment part of the report embraces, in depth Relapsed or Refractory Myelodysplastic Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed or Refractory Myelodysplastic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed or Refractory Myelodysplastic Syndrome.

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Chapters

This segment of the Relapsed or Refractory Myelodysplastic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs

CX-01: Cantex Pharmaceuticals CX-01 is a new chemical entity derived from unfractionated heparin with very low anticoagulant activity. CX-01 targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. CX-01 also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. Together, these activities are understood to sensitize AML blasts to chemotherapy and improve clinical responses. These mechanisms of action support the potential for development in myelodysplastic syndrome, multiple myeloma, and lymphomas. Currently in phase 2 of clinical trials for the treatment of Myelodysplastic Syndrome.

LP-108: Newave Pharmaceuticals Mechanism of Action: Proto-oncogene protein c-bcl-2 inhibitors. The drug is in phase 1 of clinical trials for the treatment of Relapsed or Refractory Myelodysplastic Syndrome
BTX-A51: Bio Thery XBTX-A51 appears to block a specific leukemic stem cell target (CK1-alpha) as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. BTX-A51 has demonstrated remarkable preclinical animal efficacy implying the eradication of AML stem cells and the potential for use in multiple malignancies. Currently in phase 1 of clinical trials for the treatment ofMyelodysplasticSyndrome.

Relapsed or Refractory Myelodysplastic Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Relapsed or Refractory Myelodysplastic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Relapsed or Refractory Myelodysplastic Syndrome

There are approx. 5+ key companies which are developing the therapies for Relapsed or Refractory Myelodysplastic Syndrome. The companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Parenteral

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Polymer
• Peptide
• Gene Therapy
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsed or Refractory Myelodysplastic Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed or Refractory Myelodysplastic Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed or Refractory Myelodysplastic Syndrome drugs.

Relapsed or Refractory Myelodysplastic Syndrome Report Insights

• Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Relapsed or Refractory Myelodysplastic Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Relapsed or Refractory Myelodysplastic Syndrome drugs?
• How many Relapsed or Refractory Myelodysplastic Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed or Refractory Myelodysplastic Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Relapsed or Refractory Myelodysplastic Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsed or Refractory Myelodysplastic Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cantex Pharmaceuticals
• Novartis
• Newave Pharmaceuticals
• BioTheryX
• Agios Pharmaceuticals

Key Products

• CX-01
• BTX-A51
• Ruxolitinib
• AG-120
• LP-108

This product will be delivered within 2 business days.